Brian Furman

Summary

Affiliation: University of Strathclyde
Country: UK

Publications

  1. ncbi Modulation of cyclic nucleotides and cyclic nucleotide phosphodiesterases in pancreatic islet beta-cells and intestinal L-cells as targets for treating diabetes mellitus
    Brian Furman
    University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Sciences, Taylor Street, Glasgow G4 0NR, UK
    Curr Opin Investig Drugs 7:898-905. 2006
  2. ncbi Cyclic AMP signaling in pancreatic islets
    Brian Furman
    Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4ONR, Scotland, UK
    Adv Exp Med Biol 654:281-304. 2010
  3. ncbi The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
    Brian L Furman
    Strathclyde Institute of Pharmacy and Biomedical Sciences, Robertson Wing Room 501G, 161 Cathedral Street, Glasgow G4 0RE, UK
    Toxicon 59:464-71. 2012
  4. ncbi Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review
    Brian Furman
    Department of Physiology and Pharmacology, University of Strathclyde, Strathclyde Institute for Biomedical Sciences, Taylor Street, Glasgow G4 ONR, UK
    J Pharm Pharmacol 56:1477-92. 2004

Detail Information

Publications4

  1. ncbi Modulation of cyclic nucleotides and cyclic nucleotide phosphodiesterases in pancreatic islet beta-cells and intestinal L-cells as targets for treating diabetes mellitus
    Brian Furman
    University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Sciences, Taylor Street, Glasgow G4 0NR, UK
    Curr Opin Investig Drugs 7:898-905. 2006
    ..This review will discuss the possibility of targeting cAMP mechanisms in the treatment of type 2 diabetes mellitus, in which insulin release in response to glucose is impaired...
  2. ncbi Cyclic AMP signaling in pancreatic islets
    Brian Furman
    Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4ONR, Scotland, UK
    Adv Exp Med Biol 654:281-304. 2010
    ..This chapter discusses the formation, destruction and actions of cAMP in the islets with particular emphasis on the beta-cell...
  3. ncbi The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
    Brian L Furman
    Strathclyde Institute of Pharmacy and Biomedical Sciences, Robertson Wing Room 501G, 161 Cathedral Street, Glasgow G4 0RE, UK
    Toxicon 59:464-71. 2012
    ..Exendin-4 mimicked GLP-1 through stimulating the GLP-1 receptor. The much greater stability of exendin-4 led to its experimental and clinical evaluation as an anti-diabetic agent and its introduction to the market in 2005...
  4. ncbi Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review
    Brian Furman
    Department of Physiology and Pharmacology, University of Strathclyde, Strathclyde Institute for Biomedical Sciences, Taylor Street, Glasgow G4 ONR, UK
    J Pharm Pharmacol 56:1477-92. 2004
    ....